



# Takeda Oncology Pipeline

Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugates (ADCs), complex biologics and small molecules. These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
<b>Elritercept (TAK-226)</b>	Complex biologic	<i>2L anemia-associated myelodysplastic syndromes</i>	Phase 3 	Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong and Macau. Activin A/B ligand trap
		<i>Anemia-associated myelofibrosis</i>	Phase 2 	
<b>Mirvetuximab soravtansine-gynx (TAK-853)</b> (Japan rights only)	ADC	<i>Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer</i>	Phase 3 	Takeda has development and commercialization rights for the treatment in Japan.
		<i>Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer</i>	Phase 1/2 	
<b>Rusfertide (TAK-121)</b>	Small molecule	<i>Polycythemia vera</i>	Phase 3 	Collaboration with Protagonist Therapeutics. Protagonist is responsible for development in the U.S. through the completion of the Phase 3 VERIFY trial. Takeda has rights for ex-U.S. development and is responsible for leading global regulatory and commercialization activities. Hepcidin mimetic peptide (injection)
<b>TAK-921</b>	ADC	<i>3L+ gastric cancer</i>	Phase 3 	Collaboration with Innovent Biologics. Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong, Macau and Taiwan. Ongoing Phase 3 study in 3L+ gastric cancer is being conducted in Japan and China.
		<i>Solid tumors</i>	Phase 1 	
<b>TAK-928</b>	Complex biologic	<i>2L squamous non-small cell lung cancer</i>	Phase 3 	Collaboration with Innovent Biologics. Takeda will lead global co-development and U.S. co-commercialization and has exclusive commercial rights outside the U.S. and mainland China, Hong Kong, Macau and Taiwan.
		<i>Solid tumors</i>	Phase 2 	
<b>TAK-188</b>	ADC	<i>Solid tumors</i>	Phase 1/2 	Takeda has global development and commercialization rights to TAK-188, which utilizes licensed technology from Heidelberg Pharma and Memorial Sloan Kettering Cancer Center.
<b>TAK-168</b>	Small molecule	<i>Solid tumors</i>	Phase 1 	Collaboration with Kumquat Biosciences. Kumquat is responsible for development (KQB168) through the completion of the Phase 1 trial (NCT06994806).



Learn more at [TakedaOncology.com](https://www.takedaoncology.com)  
©2026 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY